Across the pond...Nasdaq: KZIA, page-183

Management is awaiting for St Jude Children's Research Hospital to release the second part of the study of Paxalisib (GDC-0084) in DIPG.
According to management's milestone estimate, the provisional interim data is now due.
Maybe there are negotiations underway, with regards to the ASX RELEASE ON 7 August 2020, US FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION (RPDD)TO PAXALISIB FOR DIPG?

This is the release of the first stage on 12 September 2019.

https://www.prnewswire.com/news-releases/st-jude-study-of-gdc-0084-in-dipg-successfully-completes-first-stage-second-part-of-study-now-underway-300916919.html

Regards.